E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 8/28/2006 in the Prospect News Biotech Daily.

LCA Vision reiterated at market outperform

JMP Securities analyst Anthony Ostrea reiterated LCA-Vision Inc. at market outperform and a $64 price target following a visit to the company's San Mateo, Calif., location. The San Mateo center generates procedures averaging 250 to 300 per month. According to the analyst, LCA has room to take its current spend of $215 to $220 per procedure higher to drive patient volumes. In addition, the company has procedures in place to convert patients, such as a less-than five minute pre-op wait time. Shares of the Cincinnati-based laser vision correction services company were up 44 cents, or 1.03%, at $43.05, on volume of 279,698 shares versus the three-month running average of 521,969 shares. (Nasdaq: LCAV)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.